Realtime | Geld | Brief | Zeit |
---|---|---|---|
20,780 | 20,860 | 11:46 | |
20,780 | 20,860 | 11:46 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
14.11. | ALK Abello: Nine-month interim report (Q3) 2024 (unaudited) | 78 | GlobeNewswire (Europe) | Company release No. 19/2024 ALK delivers 18% organic revenue growth and an operating profit margin of 23% in Q3 Revenue growth was mainly driven by a continued strong momentum in tablet sales... ► Artikel lesen | |
09.11. | ALK Abello: ALK licenses rights to neffy, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) | 4 | GlobeNewswire (USA) | ||
07.11. | ALK Abello: Invitation to the presentation of ALK's results for the first nine months (Q3) 2024 on Thursday 14 November 2024 | 10 | GlobeNewswire (USA) | ||
27.08. | ALK Abello: Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff | 6 | GlobeNewswire (USA) | ||
23.08. | ALK-Abelló A/S reports Q2 results; raises FY24 outlook | 5 | Seeking Alpha | ||
22.08. | ALK Abello: Six-month interim report (Q2) 2024 | 236 | GlobeNewswire (Europe) | Company release No. 16/2024 ALK delivers 21% organic revenue growth with an operating profit margin of 19% in Q2 (unaudited) Revenue growth was driven by a continued strong momentum in tablet sales... ► Artikel lesen | |
22.08. | ALK Abello: ALK upgrades its full-year revenue and earnings outlook | 212 | GlobeNewswire (Europe) | ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the full-year financial outlook has been upgraded to reflect the current performance and outlook for the remainder of the year. Revenue is... ► Artikel lesen | |
ALK-ABELLO Aktie jetzt für 0€ handeln | |||||
14.08. | ALK Abello: Invitation to the presentation of ALK's results for the first six months (Q2) 2024 on Friday 23 August 2024 | 2 | GlobeNewswire (USA) | ||
21.06. | ALK Abello: ALK upgrades its full-year revenue and earnings outlook | 202 | GlobeNewswire (Europe) | ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the full-year financial outlook has been upgraded to reflect better than expected sales performance in Q2 and an improved outlook for the remainder... ► Artikel lesen | |
21.06. | ALK Abello: ALK provides update on regulatory process for the house dust mite allergy tablet in China | 170 | GlobeNewswire (Europe) | ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that it has decided to withdraw the Biologic License Application ('BLA') for its house dust mite ('HDM') sublingual allergy immunotherapy tablet... ► Artikel lesen | |
03.06. | ALK Abello: ALK launches new growth strategy and 2028 financial ambitions | 331 | GlobeNewswire (Europe) | ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the Board of Directors has adopted a new corporate strategy (Allergy+) and 2028 financial ambitions. Allergy+ aims to further strengthen ALK's... ► Artikel lesen | |
03.06. | ALK Abello: ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies | 219 | GlobeNewswire (Europe) | At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took part in Valencia in Spain from 31 May to 3 June 2024, the Danish pharmaceutical company ALK presented... ► Artikel lesen | |
30.05. | ALK Abello: ALK's European registration application for ITULAZAX for paediatric indication accepted for review | 206 | GlobeNewswire (Europe) | ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the European regulatory filing for ITULAZAX® (tree sublingual allergy immunotherapy (SLIT) tablet) in young children has been accepted for review... ► Artikel lesen | |
29.05. | ALK Abello: Listen in on ALK's Capital Markets Day on 4 June 2024 | 5 | GlobeNewswire (USA) | ||
02.05. | ALK Abello: Three-month interim report (Q1) 2024 (unaudited) | 100 | GlobeNewswire (Europe) | Company release No. 11/2024 ALK delivers 10% organic revenue growth with operating profit up 41% in Q1 and upgrades outlookThe growth in ALK's overall sales was primarily driven by the European tablet... ► Artikel lesen | |
02.05. | ALK Abello: ALK upgrades its full-year revenue outlook | 141 | GlobeNewswire (Europe) | ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the 2024 full-year financial outlook has been updated. Revenue is now expected to grow by 10-13% in local currencies (previously: 9-12%). The... ► Artikel lesen | |
08.02. | ALK Abello: Annual report 2023: ALK delivers 9% sales growth with profits up 50% | 413 | GlobeNewswire (Europe) | 08 February 2024 ALK's (ALKB:DC / OMX: ALK B / AKBLF) Board of Directors has approved the company's 2023 annual report. Following a robust performance in Q4, full-year results were in line with the... ► Artikel lesen | |
07.02. | ALK Abello: ALK and McMaster researchers discover new cell that remembers allergies | 349 | GlobeNewswire (Europe) | Researchers with McMaster University and Denmark-based pharmaceutical company ALK-Abelló A/S have made a ground-breaking discovery: a new cell that remembers allergies. The discovery gives scientists... ► Artikel lesen | |
05.02. | ALK Abello: ALK's 2030 CO2 reduction targets have been approved by SBTi | 680 | GlobeNewswire (Europe) | ALK's near-term carbon reduction targets for scope 1, 2 and 3 have been validated and approved by the Science Based Targets initiative.
Today, ALK announces that its near-term carbon reduction targets... ► Artikel lesen | |
04.01. | ALK Abello: ALK to become sole manufacturer and distributor of skin antigen test for penicillin allergy | 353 | GlobeNewswire (Europe) | - PRE-PEN® (benzylpenicilloyl polylysine injection USP) is the only FDA-approved diagnostic skin test for the evaluation of penicillin allergyi,ii - The Danish, pharmaceutical company ALK (ALKB:DC... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BAYER | 19,222 | -1,65 % | Daimler-Truck, dynaCERT, Bayer AG: Gegensätze im 3. Quartal: Etablierte unter Druck, Newcomer mit Durchbruch | Etablierte DAX-Konzerne wie die Bayer AG und Daimler Truck, ein Unternehmen der Mercedes-Benz Gruppe, kämpfen im dritten Quartal 2024 mit Gegenwind. Doch der kanadische Cleantech-Spezialist dynaCERT... ► Artikel lesen | |
PFIZER | 23,595 | -0,32 % | UBS stuft PFIZER INC auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Pfizer nach einer UBS-Konferenz auf "Neutral" mit einem Kursziel von 31 US-Dollar belassen. Nach einem bisher durchwachsenen... ► Artikel lesen | |
NOVO NORDISK | 97,56 | -2,44 % | Novo Nordisk informiert Patient:innen über Möglichkeiten der Wochentherapie bei Typ 2 Diabetes | Mainz (ots) - Dank intensiver Forschung konnten in der medikamentösen Behandlung von Typ 2 Diabetes in den vergangenen Jahren große Fortschritte erreicht werden. So können heutige Injektionstherapien... ► Artikel lesen | |
NOVARTIS | 97,83 | -0,02 % | UBS stuft NOVARTIS AG auf 'Buy' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Novartis nach einer UBS-Konferenz auf "Buy" mit einem Kursziel von 111 Franken belassen. Finanzchef Harry Kirsch habe sich... ► Artikel lesen | |
MERCK KGAA | 138,00 | -0,07 % | Merck Aktie: Optimismus überwiegt im Vorstand | Der DAX-Konzern Merck KGaA verzeichnet im dritten Quartal 2024 einen bemerkenswerten Aufschwung. Der Umsatz stieg um 1,8 Prozent auf 5,3 Milliarden Euro, während das bereinigte operative Ergebnis um... ► Artikel lesen | |
GILEAD SCIENCES | 84,39 | +0,36 % | Gilead's Livdelzi Shows Sustained Efficacy, Long-Term Safety In PBC Management | FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% of participants with... ► Artikel lesen | |
AURORA CANNABIS | 4,010 | -0,45 % | Aurora Cannabis Inc (3): Aurora Cannabis releases new recreational products | ||
SANOFI | 90,55 | +0,21 % | Aktienmarkt: Aktie von Sanofi SA tritt auf der Stelle (93,74 €) | Im Wertpapierhandel ist die Aktie von Sanofi SA gegenwärtig unauffällig. Zuletzt zahlten Investoren für das Wertpapier 93,74 Euro. Kaum auffällig ist derzeit an der Börse der Kurs von Sanofi SA. Die... ► Artikel lesen | |
GSK | 15,880 | +0,44 % | Dividendenbekanntmachungen (14.11.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABRDN PROPERTY INCOME TRUST LIMITED GB0033875286 0,003 GBP 0,0036 EUR AFFILIATED MANAGERS GROUP INC US0082521081 0,01 USD 0,0094... ► Artikel lesen | |
ABBVIE | 160,18 | +0,65 % | European Commission Approves AbbVie's ELAHERE For Platinum-Resistant Ovarian Cancer Treatment | WASHINGTON (dpa-AFX) - AbbVie (ABBV) announced that the European Commission approved ELAHERE or mirvetuximab soravtansine for the treatment of adult patients with folate receptor-alpha (FR?)... ► Artikel lesen | |
CANOPY GROWTH | 3,615 | +1,40 % | Jetzt wird es brenzlig: Kurse von Tilray, Canopy & Co. brechen massiv ein. So heftig könnte es werden | © Foto: Piyapong Thongdumhyu - 123rf StockfotoRund um die US-Wahl fielen weitere Entscheidungen. Während der Cannabis-Sektor die Wahl Trumps zum nächsten US-Präsidenten noch nicht so ganz einordnen... ► Artikel lesen | |
ROCHE | 269,30 | +0,45 % | Roche Aktie: Erfolgreicher Meilenstein erreicht! | ||
STADA ARZNEIMITTEL | - | - | Genpact und STADA erneuern mehrjährige Partnerschaft zur Verbesserung von Finanzprozessen | München (ots/PRNewswire) - STADA nutzt die Expertise von Genpact in den Bereichen Daten, Technologie und künstlicher Intelligenz, um seine Finanzorganisation für die Zukunft fit zu machen und sich Wettbewerbsvorteile... ► Artikel lesen | |
MERCK & CO | 92,30 | -0,22 % | Merck & Co., Inc.: Merck Foundation Announces $17 Million U.S. Initiative To Expand Access to High-Quality Cardiac Care | RAHWAY, NJ / ACCESSWIRE / November 20, 2024 / The Merck Foundation (Foundation) has announced a new initiative to help advance equitable access to high-quality, culturally responsive care for people... ► Artikel lesen | |
ELI LILLY | 711,10 | -0,41 % | Dividendenbekanntmachungen (15.11.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 3M COMPANY US88579Y1010 0,7 USD 0,6646 EUR ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,0712 EUR AGCO CORPORATION US0010841023 0... ► Artikel lesen |